End-Stage Renal Disease, Renal Failure, Chronic
Conditions
Keywords
Renal disease, renal impairment, End stage renal disease, Healthy volunteer, Pharmacokinetics
Brief summary
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD) compared to healthy volunteers.
Interventions
DRUGSerelaxin
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
All subjects \- at least 50 years; body mass index (BMI) within the range of 18 - 35 kg/m2. Patients with severe renal impairment / ESRD * Severe renal impairment (clinically significantly abnormal creatinine and creatinine clearance (15mL/min/1.73m2≤eGFR\<30mL/min/1.73m2) or ESRD on hemodialysis. * Sitting vital signs should be within the following ranges: * oral body temperature between 35.0-37.5 °C * systolic blood pressure, 110 to 170 mm Hg * diastolic blood pressure, 60 to 105 mm Hg * pulse rate, 45 - 100 bpm Healthy subjects * eGFR \> 90mL/min/1.73m2; * matching in race, age (±10 years), gender, BMI (±15%) to a subject with renal impairment * Subject must be in good health. * Sitting vital signs should be within the following ranges: * oral body temperature between 35.0-37.5 °C * systolic blood pressure, 100 to 150 mm Hg * diastolic blood pressure, 60 to 95 mm Hg * pulse rate, 50 to 100 bpm
Exclusion criteria
All subjects * History of clinically significant ECG abnormalities at Screening or Baseline. * Pregnant or nursing (lactating) women * Women of child-bearing potential unless they are using highly effective methods of contraception during dosing of study treatment. * Sexually active males (incl. vasectomized men) must use a condom during intercourse while taking drug and for 2 weeks after stopping study medication. * Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.). Patients with severe renal impairment / ESRD: * Presence of any non-controlled and clinically significant disease, surgical or medical condition that could affect the study outcome or that would place the patient at undue risk as judged by the investigator. * Hemoglobin levels below 9.0 g/dL at screening and baseline, other laboratory parameters at screening and baseline outside acceptable limits . * Treatment with any cytostatic drug or autonomic alpha blocker. Healthy subjects: * Use of any prescription drugs (other than hormonal contraception, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. * History or presence of any disease, surgical or medical condition of any major system organ class considered clinically significant by the investigator. * Laboratory parameter at screening and baseline outside of normal limits. For small deviations which could be attributed to the characteristics of the subjects (e.g. age) it will be to the discretion of the investigator to consider them as exclusive or not. * A positive Hepatitis B surface antigen or Hepatitis C test result.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) | pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15 | Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin |
| The area under the serum concentration-time curve from time zero to 28 hours after administration (AUC 0-28hr) | pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15 | Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin |
| The area under the serum concentration-time curve from time zero to infinity (AUCinf) | pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15 | Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin |
| The observed maximum serum concentration following drug administration (Cmax) | pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15 | Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients with reported adverse events, serious adverse events and death. | From Day -21 to Day 15 |
| Percentage of patients developing anti-RLX030 antibodies | Day 1 (pre-treatment) and Day 15 |
Countries
Germany
Outcome results
None listed